Alnylam Pharmaceuticals, Inc. has announced the FDA approval of its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. This approval expands the indication for AMVUTTRA, making it the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Company Information
Company
Alnylam Pharmaceuticals
Location
Cambridge, Massachusetts, United States
About
Alnylam Pharmaceuticals, Inc. is a leading RNAi therapeutics company focused on developing novel medicines to treat genetically defined diseases. The company is committed to bringing innovative treatments to patients suffering from serious conditions. Their investigational product vutrisiran is designed to treat transthyretin amyloidosis with cardiomyopathy, aiming to improve patient outcomes through advanced therapeutic approaches.
CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma